FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Expression Vector topics
Expression Vector
Recombinant
Nucleic Acid
Antibodies
Polypeptide
Amino Acid
Amino Acid Sequence
Nucleic Acids
Polynucleotide
Nucleotide
Cytomegalovirus
Endothelial
Extracellular
Endothelial Cell
Epithelial

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Expression Vector patents



      
           
This page is updated frequently with new Expression Vector-related patent applications. Subscribe to the Expression Vector RSS feed to automatically get the update: related Expression RSS feeds. RSS updates for this page: Expression Vector RSS RSS


Date/App# patent app List of recent Expression Vector-related patents
01/22/15
20150024498
 Cldn5 mini-promoters patent thumbnailCldn5 mini-promoters
Isolated polynucleotides comprising a cldn5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia
01/22/15
20150024036
 Targeting rnas to microvesicles patent thumbnailTargeting rnas to microvesicles
Disclosed herein is an isolated nucleic acid molecule comprising a first nucleic acid sequence 5′-accctgccgcctggactccgcctgt-3′ (seq id no: 22), or a functional variant thereof, operably linked to a second, heterologous nucleic acid sequence. The isolated nucleic acid molecule can be dna (in an expression vector) and rna (mrna, shrna, orncrna).
The General Hospital Corporation
01/22/15
20150023988
 Potent and selective inhibitors of nav1.7 patent thumbnailPotent and selective inhibitors of nav1.7
Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of nav1.7.
Amgen Inc.
01/15/15
20150017692
 Beta-glucosidase patent thumbnailBeta-glucosidase
The present invention relates to a polypeptide which has β-glucosidase activity, and which includes an amino acid sequence represented by seq id no: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by seq id no: 1, or a polypeptide including an amino acid sequence having 92% or greater sequence identity with the amino acid sequence represented by seq id no: 1. According to the present invention, a novel β-glucosidase enzyme derived from acremonium cellulolyticus, a polynucleotide encoding the β-glucosidase, an expression vector for expressing the β-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the β-glucosidase can be provided..
Honda Motor Co., Ltd.
01/15/15
20150017691
 ß-glucosidase patent thumbnailß-glucosidase
The present invention relates to a polypeptide which has β-glucosidase activity, and which includes an amino acid sequence represented by seq id no: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by seq id no: 1, or a polypeptide including an amino acid sequence having 92% or greater sequence identity with the amino acid sequence represented by seq id no: 1. According to the present invention, a novel β-glucosidase enzyme derived from acremonium cellulolyticus, a polynucleotide encoding the β-glucosidase, an expression vector for expressing the β-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the β-glucosidase can be provided..
Honda Motor Co., Ltd.
01/15/15
20150017690
 Beta-glucosidase patent thumbnailBeta-glucosidase
The present invention relates to a polypeptide which has β-glucosidase activity, and which includes an amino acid sequence represented by seq id no: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by seq id no: 1, or a polypeptide including an amino acid sequence having 91% or greater sequence identity with the amino acid sequence represented by seq id no: 1. According to the present invention, a novel β-glucosidase enzyme derived from acremonium cellulolyticus, a polynucleotide encoding the β-glucosidase, an expression vector for expressing the β-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the β-glucosidase can be provided..
Honda Motor Co., Ltd.
01/15/15
20150017689
 ß-glucosidase patent thumbnailß-glucosidase
The present invention relates to a polypeptide which has β-glucosidase activity, and which includes an amino acid sequence represented by seq id no: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by seq id no: 1, or a polypeptide including an amino acid sequence having 90% or greater sequence identity with the amino acid sequence represented by seq id no: 1. According to the present invention, a novel β-glucosidase enzyme derived from acremonium cellulolyticus, a polynucleotide encoding the β-glucosidase, an expression vector for expressing the β-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the β-glucosidase can be provided..
Honda Motor Co. Ltd.
01/15/15
20150017173
 Antibodies to human transmembrane proteins patent thumbnailAntibodies to human transmembrane proteins
The invention provides human transmembrane proteins (htmpn) and polynucleotides which identify and encode htmpn. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation
01/15/15
20150017121
 Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy patent thumbnailCombination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an il-12 polypeptide having a biological activity of il-12 or a nucleic acid expression vector comprising a sequence encoding such il-12 polypeptide, and a non-agonist ctla-4 ligand or non-agonist pd-1 ligand, particularly an anti-ctla-4 or anti-pd-1 immunoglobulin g..
Universitat Zurich
01/08/15
20150010518
 Nr2e1 mini-promoters patent thumbnailNr2e1 mini-promoters
Isolated polynucleotides comprising a nr2e1 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia
01/01/15
20150005473

Recombinant expression vector system for variants of coagulation factor viii and von willebrand factor


Disclosed is an expression vector system for variants of coagulation factor viii (fviii) and von willebrand factor (vwf). In detail, mutant vwf the size of which is significantly reduced by deleting exons but which has remarkably increased fviii stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with fviii are disclosed.
Korea University Industrial & Academic Collaborative Foundation
01/01/15
20150004165

Secreted proteins


The invention provides human secreted proteins (secp) and polynucleotides which identify and encode secp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation
01/01/15
20150004129

Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins


The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component a and at least one component b, whereby component a contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component b contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules.
Topotarget Switzerland Sa
12/25/14
20140378678

Compositions and methods for recombinant synthesis of high molecular weight hyaluronic acid


Provided is a novel hyaluronan synthase (has2), isolated nucleic acids encoding it, and expression vectors which express the novel has2. Also provided are cell cultures which contain cells which harbor the expression vectors, methods of using the cell cultures to produce high molecular weight hyaluronic acid, and cell culture media that contains the high molecular weight hyaluronic acid..
University Of Rochester
12/25/14
20140378389

T cell receptors recognizing hla-a1- or hla-cw7-restricted mage


The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for a) melanoma antigen family a (mage a)-3 in the context of hla-a1 or b) mage-a12 in the context of hla-cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
12/25/14
20140377869

Importation of mitochodrial protein by an enhanced allotopic approach


An expression vector containing appropriate mitochondrion-targeting sequences (mts) and appropriate 3′utr sequences provides efficient and stable delivery of a mrna encoding a protein (cds) to the mitochondrion of a mammalian cell. The mts and 3′utr sequences guide the cds mrna from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the cds is translated.
Institut National De La Sante Et De La Recherche Medicale (inserm)
12/25/14
20140377801

Artificial signal peptide for expressing an insoluble protein as a soluble active form


The present invention relates to expression vectors and methods for enhancing soluble expression and secretion of an insoluble heterologous protein, particularly a bulky folded active heterologous protein which has one or more transmembrane-like domains or intramolecular disulfide bonds by linking a leader peptide with acidic or basic pl and high hydrophilicity thereto; by substituting one or more amino acids within n-terminal of the heterologous protein with ones having acidic or neutral pl and high hydrophilicity; or reducing elevating Δgrna value of a polynucleotide encoding the leader peptide having basic pl value and high hydrophilicity. The expression vector and the method may be used to produce of heterologous protein and to transduce of therapeutic proteins in a patient by preventing formation of insoluble inclusion body and by enhancing secretional efficiency of the heterologous protein into the periplasm or outside cell..
Republic Of Korea (republic Of National Fisheries Research And Development Institute)
12/18/14
20140373192

High efficiency plant expression promotor from capcicum annuum serine hydroxymethyl transferase gene and uses thereof


A high efficiency plant expression promoter from capsicum annuum serine hydroxymethyl transferase gene and uses thereof. This high efficiency plant expression promoter and 5′-untranslated region (5′-utr) from capsicum annular, serine hydroxymethyl transferase gene, a high efficiency plant expression vector having the same, a plant transformed with said vector, a process for high efficiency expression of a foreign gene by using said vector and a transformed plant which expresses with high efficiency a foreign gene based on said process and seeds of the transformed plant..
Industry Foundation Of Chonnam National University
12/18/14
20140370547

Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides


Herein is reported an expression vector comprising—an antibody light chain expression cassette,—an antibody heavy chain expression cassette, and—a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5′ to 3′ sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies..
Hoffmann-la Roche Inc.
12/18/14
20140369979

Vector simultaneously expressing dodecameric trail and hsv-tk suicide genes, and anticancer stem cell therapeutic agent using same


The present invention relates to a dna cassette comprising a nucleotide sequence encoding dodecameric trail and a suicide gene nucleotide sequence, a recombinant expression vector comprising the dna cassette, a recombinant adenovirus prepared by using the recombinant expression vector, a host cell transduced with the recombinant adenovirus, a composition for treating cancer comprising the host cell, and a method for treating cancer comprising the step of administering the composition for treating cancer to a subject. The stem cell therapy coexpressing dodecameric trail and hsv-tk by introduction of the dna cassette of the present invention has more excellent anticancer effects than the known therapy, and thus can be effectively used in the treatment of many different types of solid tumors and metastatic tumors..
Biod Co., Ltd.
12/11/14
20140366219

Increasing soybean defense against pests


Disclosed are pest resistance genes isolated from soybean. In several embodiments, a pest resistance gene isolated from soybean includes a nucleic acid sequence at least 80% identical to seq id no: 1 or seq id no: 2 or a degenerate variant thereof, or a fragment thereof.
12/11/14
20140363860

Omega-3 desaturase used in the biosynthesis of polyunsaturated fatty acids


The present invention provides novel fatty acid desaturases genes used for synthesis of polyunsaturated fatty acids, especially ω3 desaturases (fads15). The present invention also provides nucleic acid sequence coding the above-described desaturases, expression vector of the above-described desaturases and recombinant microorganism expressing above-described desaturases..
12/04/14
20140359798

Correction of crb1 mutations


Genetically engineered mice having a corrected cbr1rd8 mutation and methods for correcting the cbr1rd8 mutation to produce the genetically engineered mice are provided according to aspects of the present invention. Kits, expression vectors and fusion proteins according to aspects of the invention are provided for use to produce the genetically engineered mice characterized by a corrected cbr1rd8 mutation..
12/04/14
20140356929

Expression vector for an improved protein secretion


The aim of the invention is to improve the secretion of a protein from a host cell in order to increase the product yield of protein in a fermentation process. This is achieved by an expression vector comprising a) a promoter sequence and b) a nucleic acid sequence that codes for a protein.
12/04/14
20140356346

Modified coagulation factor viia with extended half-life


The present invention relates to the fields of factor vii (fvii) and factor viia (fviia) albumin linked polypeptides. More specifically, the invention relates to cdna sequences coding for human factor vii and factor viia and derivatives genetically fused to a cdna coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cdna sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives.
12/04/14
20140356342

Human beta-adrenergic receptor kinase polypeptide and methods


Various embodiments of the invention provide human kinases and phosphatases (kpp) polypeptides and polynucleotides which identify and encode kpp. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists.
12/04/14
20140352706

Isopropylmalate synthase from nicotiana tabacum and methods and uses thereof


The present invention relates to a mutant, non-naturally occurring or transgenic plant cell comprising: (i) at least one polynucleotide comprising, consisting or consisting essentially of a sequence encoding an isopropylmalate synthase and having at least 60% sequence identity to seq id no:1 or seq id no:10 or seq id no: 12 or seq id no:14; or (ii) a polypeptide encoded by said polynucleotide(s); or (iii) a polypeptide having at least 60% sequence identity to seq id no:2 or seq id no:11 or seq id no:13 or seq id no:15; or (iv) a construct, vector or expression vector comprising said polynucleotide sequence(s), optionally wherein said construct, vector or expression vector additionally comprises a promoter comprising, consisting or consisting essentially of the sequence set forth in seq id no:8 or a variant thereof with at least about 60% identity thereto or a trichome promoter.. .
11/27/14
20140350047

Isoform-selective inhibitors and activators of pde3 cyclic nucleotide phosphodiesterases


The present invention concerns methods and compositions related to type 3 phosphodiesterases (pde3). Certain embodiments concern isolated peptides corresponding to various pde3a isoforms and/or site-specific mutants of pde3a isoforms, along with expression vectors encoding such isoforms or mutants.
11/27/14
20140349370

Novel vector containing multiple nucleotide sequences for the expression of enzymes


An expression vector is provided. The vector includes a promoter configured to drive the expression of the transgene in the cell.
11/27/14
20140348893

Rnai for the control of insects and arachnids


The present invention describes a new non-compound based approach for insect and/or arachnid control. The present inventors have identified for the first time novel targets for rnai, which can effectively control insect and/or arachnid pest populations.
11/27/14
20140348785

Neutralizing gp41 antibodies and their use


Monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids.
11/27/14
20140348743

Monoclonal antibodies to programmed death 1 (pd-1)


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
11/20/14
20140342407

Neutralizing gp41 antibodies and their use


Monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids.
11/20/14
20140342401

Promoter derived from human gene


The present invention relates to a transfected mammalian host cell whose ability to secrete a foreign protein has been enhanced by using a foreign gene expression vector having a promoter derived from a human gene, and a method for producing the foreign protein using the host cell. A method for enhancing the production of a foreign protein to be used in a pharmaceutical protein product in a host cell such as a cultured mammalian cell is provided.
11/20/14
20140341897

Anti-folate receptor alpha antibodies and uses thereof


Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits.
11/20/14
20140341852

Capsid-modified raav vector compositions and methods therefor


Disclosed are capsid-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated raav constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors.
11/13/14
20140335622

Expression vector and producing protein


Provided are: an expression vector for secreting a protein (z) to be recovered or a fusion protein having the protein (z) moiety therein; a method for producing a transformant using the expression vector; the transformant; and a method for producing a protein using the transformant. An expression vector comprising an expression cassette containing a structural gene sequence (y) encoding a protein (y), a structural gene sequence (z) located downstream from the structural gene sequence (y) and encoding a protein (z) that is a protein to be recovered, and a promoter sequence and a terminator sequence for expressing a fusion protein containing the protein (y) moiety and the protein (z) moiety, characterized in that the protein (y) is a full-length protein of protein disulfide isomerase 1 (pdi1), a partial protein of pdi1, or a mutant protein of the full-length protein or the partial protein..
11/13/14
20140335516

Inducible cell-based model for the study of friedreich's ataxia


Isolated transduced cells exhibiting frda characteristics in an inducible fashion are disclosed. Isolated transduced cells comprise an expression vector having a nucleic acid sequence encoding an shrna for frataxin protein knockdown and a heterologous expression control sequence.
11/13/14
20140335097

Expression vector


The present invention provides an expression vector for cell-surface expression of proteins.. .
11/06/14
20140331360

Plant viral expression vectors and use of same for generating genotypic variations in plant genomes


A method of generating genotypic variation in a genome of a plant is disclosed. The method comprising introducing into the plant at least one viral expression vector encoding at least one chimeric nuclease which comprises a dna binding domain, a nuclease and a localization signal to a dna-containing organelle, wherein the dna binding domain mediates specific targeting of the nuclease to the genome of the plant, thereby generating genotypic variation in the genome of the plant..
11/06/14
20140328833

Methods for treating cancer using anti-pd-1 antibodies


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/30/14
20140322778

Production of isopropanol by improved recombinant strains


The expression vector includes: the nucleic acids coding for the polypeptides forming a polypeptide complex having an enzyme activity allowing acetoacetyl-coa to be converted to acetoacetate; optionally, at least one nucleic acid coding for a polypeptide having an enzyme activity allowing acetoacetate to be converted to acetone; and at least one nucleic acid coding for a polypeptide having an enzyme activity allowing acetone to be converted to isopropanol; the expression of the nucleic acids being controlled by a single constitutive promoter located upstream of the abovementioned nucleic acids.. .
10/30/14
20140322301

Mucin antigen vaccine


Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.
10/30/14
20140322205

Rtef-1 variants and the use thereof for inhibition of angiogenesis


Dominant negative (dn) variants of transcriptional enhancer factor 1-related (rtef-1) are described. Dn rtef-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription.
10/30/14
20140322160

Method and composition for altering a b cell mediated pathology


The present invention provides compositions for altering a b cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins.
10/23/14
20140317785

Specific genetic modification of the activity of trehalose-6-phosphate synthase and expression in a homologous or heterologous environment


A method for the preparation of a eukaryotic organism, for example selected from plants, animals and fungi, showing constitutive, inducible and/or organ specific expression of a specifically modified tps gene, which comprises the steps of providing a tps gene; designing a suitable modification to the tps gene by aligning the gene with the corresponding gene of yeast and establishing which part of the gene extends beyond the 5′ terminus of the yeast gene; deleting or inactivating a part of the n-terminal region of the tps gene extending beyond the 5′ terminus of the yeast gene, in order to achieve an increased trehalose-6-phosphate synthase activity; cloning the thus modified gene into an expression vector under the control of a constitutive, inducible and/or organ-specific promoter; transforming a plant cell or tissue with the thus obtained expression vector; and regenerating a complete plant from the transformed plant cell or tissue.. .
10/23/14
20140315987

Cholecystokinin b receptor (cckbr) mini-promoters


Isolated polynucleotides comprising a cckbr mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
10/23/14
20140315272

Novel lipolytic enzyme lip2


The present invention provides a novel nucleic acid sequence, designated lip2, encoding a lipolytic enzyme and the corresponding encoded amino acid sequences. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding at least one novel lipolytic enzyme, recombinant lipolytic enzyme proteins and methods for producing the same..
10/23/14
20140315247

Expression cassette, use of the expression cassette, expression vector, prokaryotic host cell comprising expression vector, bacterial strain and a producing a polypeptide


The subject matters of invention relate to expression cassette, use of the expression cassette, expression vector, prokaryotic host cell harbouring expression vector, bacterial strain, and method for producing a polypeptide. In more detail, the invention relate to stable expression of recombinant polypeptides, in systems with no need of using antibiotics.
10/23/14
20140315234

Method to generate dopaminergic neurons from mouse and human cells


The present invention relates to a method for reprogramming a differentiated non neuronal cell into a dopaminergic neuron comprising the step of inducing the expression in the differentiated non neuronal cell of at least the protein encoded by the mash1 human gene or orthologues thereof and the protein encoded by the nurr1 human gene or orthologues thereof, expression vectors, reprogrammed dopaminergic neuron and uses thereof.. .
10/23/14
20140314858

Ipnv-isav bivalent vaccine using a virus-like particle-based platform and methods of using the same


The present invention provides bivalent oral vaccines against infectious pancreatic necrosis virus (ipnv) and infectious salmon anemia virus (isav). Yeast cells comprise an expression vector comprising (i) a polynucleotide sequence encoding a vp2 capsid protein of ipnv and (ii) a polynucleotide sequence encoding one or more antigenic epitopes of hemaglutinin of isav.
10/16/14
20140308731

Novel cytochrome p450 enzymes from sorghum bicolor


Two novel cytochrome p450 genes are isolated from sorghum, each gene encoding a protein having pentadecatrienyl resorcinol hydroxylase activity. Expression vectors containing these sequences are made and used to elevate levels of pentadecatrienyl resorcinol hydroxylase in transgenic cells and organisms..
10/16/14
20140308240

Therapeutic agent for infections, and treatment method using same


(means for solving problems) the present invention provides a therapeutic agent for infections comprising as active ingredient: 15k granulysin, a combination of 15k granulysin and 15k granulysin in vivo expression vector, a combination of 15k granulysin and at least one interleukin selected from il-6, il-23 or il-27, a combination of 15k granulysin in vivo expression vector and at least one interleukin selected from il-6, il-23 or il-27, or a combination of 15k granulysin in vivo expression vector and hsp65dna and il-12dna in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.. .
10/02/14
20140296320

Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide


The present invention relates to the combinatorial use of an sirna targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.. .
10/02/14
20140296137

Methods and compositions for controlling rotifers


Described herein are compositions and methods for controlling, inhibiting, reducing and/or preventing rotifer growth with antimicrobial peptides. Methods for removing and/or preventing rotifer infestations in algae cultivations by controlling, inhibiting, reducing and/or preventing rotifer growth with an antimicrobial peptide (amp) are further provided.
10/02/14
20140296101

Secreted proteins and uses thereof


The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies.
10/02/14
20140295497

Vectors and host cells comprising a modified sv40 promoter for protein expression


The present disclosure is directed to expression vectors, comprising a weakened sv40 promoter, and recombinant mammalian cells capable of producing high levels of a polypeptide of interest, methods of generating and using such recombinant mammalian cells.. .
10/02/14
20140294941

Anti-angiogenic compositions and therapeutic applications thereof


There is described the use of the human herpesvirus type 6 (hhv-6) u94 gene and its product, the protein rep, expression vectors and pharmaceutical compositions suitable for the delivery of the u94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a subject in need thereof.. .
10/02/14
20140294867

Site-specific antibody-drug conjugation through glycoengineering


The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or adcs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
10/02/14
20140294852

Monoclonal antibodies to programmed death 1 (pd-1)


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/02/14
20140294813

Tnf binding proteins


Provided are tnf binding proteins and methods of treatment using the same. Also provided are nucleic acids encoding the binding proteins and recombinant expression vectors and host cells for making such binding proteins..
09/25/14
20140289901

Modulating beta-damascenone in plants


A mutant, non-naturally occurring or transgenic plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a neoxanthin synthase and having at least 60% sequence identity to seq id no:1 or seq id no. 6; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide having at least 66% sequence identity to seq id no:2 or at least 60% sequence identity to seq id no.
09/25/14
20140287480

Hbv polymerase mutants


The present invention relates to polymerase hbv mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to hbv with the goal of providing a protective or therapeutic effect against hbv infection..
09/25/14
20140286954

Tau protease compositions and methods of use


Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays..
09/25/14
20140286907

Transient expression vectors, preparation and uses thereof


The present invention describes a recombinant retroviral vector which cannot by itself achieve complete reverse transcription as well as its uses, in particular for transiently transferring in vitro, ex vivo or in vivo at least one ribonucleic acid sequence of interest in a cell. Such a transient transgene expression is of interest in the context of research, therapy and more generally in the field of biotechnology..
09/18/14
20140283208

Novel insecticidal proteins and methods of use


Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
09/18/14
20140283157

Lipoprotein-associated phospholipase a2 antibody compositions and methods of use


The invention provides isolated anti-lp-pla2 antibodies that bind to lp-pla2. The invention also encompasses compositions comprising an anti-lp-pla2 antibody.
09/18/14
20140283154

Transgenic insect cells comprising a bacterial glcnac-6-p 2prime-epimerase


The present invention relates to methods of facilitating the expression of recombinant polypeptides from cells, extracellular fluids, extracellular fibers, or any combination thereof, obtained from transgenic insect cells and larvae comprising a bacterial glcnac-6-p 2′-epimerase (gnpe), which is capable of converting n-acetyl-d-glucosamine-6-phosphate (glcnac-6-p) to n-acetyl-d-mannosamine-6-phosphate (mannac-6-p). The invention relates to methods to promote efficient glycoconjugate sialylation, by providing simpler ways to produce large intracellular pools of sialic acid precursors.


Popular terms: [SEARCH]

Expression Vector topics: Expression Vector, Recombinant, Nucleic Acid, Antibodies, Polypeptide, Amino Acid, Amino Acid Sequence, Nucleic Acids, Polynucleotide, Nucleotide, Cytomegalovirus, Endothelial, Extracellular, Endothelial Cell, Epithelial

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.396

3872

2 - 1 - 73